Detalhe da pesquisa
1.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Lancet
; 401(10373): 281-293, 2023 01 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36566761
2.
Optimal sample size division in two-stage seamless designs.
Pharm Stat
; 2024 Apr 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38676420
3.
Bayesian model of disease progression in mucopolysaccaridosis IIIA.
Stat Med
; 41(18): 3579-3595, 2022 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35567343
4.
The Use of Historical Controls in Clinical Trials.
JAMA
; 330(15): 1484-1485, 2023 10 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37768654
5.
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
BMJ Open
; 13(8): e069176, 2023 08 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37550022
6.
Identification of metabolic changes in genetically unstable stem cells by using model analysis of gene expression.
Chem Biodivers
; 9(5): 911-29, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22589092
7.
Cardiovascular information systems.
Healthc Inform
; 29(1): 23-7, 2012 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-22352139
8.
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs
; 82(15): 1527-1538, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36287379
9.
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs
; 82(15): 1539, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36342618